Technology
Health
Biotechnology

CohBar

$3.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-3.44%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CohBar and other stocks, options, ETFs, and crypto commission-free!

About

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. Read More The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Pasadena, CA.

Employees
12
Headquarters
Pasadena, California
Founded
2007
Market Cap
131.57M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
102.73K
High Today
$3.25
Low Today
$3.03
Open Price
$3.18
Volume
33.84K
52 Week High
$10.79
52 Week Low
$2.55

Collections

Technology
Health
Biotechnology
Research And Development
Therapy
Cancer Prevention
2017 IPO
US

News

Seeking AlphaMar 21

CohBar Inc. And CB4211 In NASH: What's The Story?

In spite of the potential clinical promise of CB4211, CohBar is high risk until the safety signals have been successfully addressed in a Phase 2 NASH trial.

2

Earnings

-$0.11
-$0.11
-$0.10
-$0.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.